Summary
Schizophrenia is a heterogeneous behavioral and cognitive syndrome involving chronic or recurrent psychosis. The disorder is characterized by several symptom domains including positive symptoms (such as hallucinations or delusions and disorganized speech), negative symptoms (such as a flat affect and poverty of speech), and cognitive deficits (including attention, memory, and executive functions). A multitude of antipsychotic products are currently available for the pharmacological management of schizophrenia, many of which are already available as inexpensive generics. Further patent and exclusivity losses in key franchises throughout the forecast period will act as a barrier to growth in the 7MM, making the schizophrenia market more competitive and crowded. Growth in the schizophrenia market is expected to be driven by the potential introduction of six promising late-stage pipeline products into the market during the forecast period, all of which are directed towards significant unmet needs.
Highlights
Key Questions Answered
- The schizophrenia market is widely genericized and many of the unexpired patents are due to expire during the forecast period. In light of this, what are the current clinical and environmental unmet needs? Will there be opportunities in this market for drug developers throughout the forecast period?
- There are five substantial unmet needs that exist in the schizophrenia market. Will pipeline drugs fulfil any of the unmet needs for schizophrenia? Which unmet needs will continue to provide opportunity for drug developers during the forecast period?
- Out of the nine late-stage pipeline products, six of these are expected to launch during the forecast period to 2025. What impact will these drugs have on the market? How will they affect the treatment algorithm for schizophrenia?
Key Findings
- The main driver of growth in the schizophrenia market will be the uptake of novel pipeline products, such as Minerva Neuroscience’s MIN-101, Intra-Cellular Therapies’ ITI-007, and Alkermes’ ALKS-3831. The pipeline products are forecast to account for 36.2% of the schizophrenia market by 2025 in the 7MM.
- Several pharma companies have focused on developing long acting injectable (LAI) formulations of their oral brands to tailor treatment plans according to patient’s individual needs and improve patient compliance, which is a notable unmet need. Despite the growing popularity of LAIs, this segment is becoming increasingly competitive with three further late-stage pipeline products expected to be launched during the forecast period.
- There are currently no products approved for the treatment of negative symptoms or cognitive impairments associated with schizophrenia, and only one drug approved for treatment-resistant patients. These constitute the major unmet needs in the schizophrenia market.
- The biggest barrier for growth in the schizophrenia market will be fierce competition from generic products. This limits market opportunities for new and existing players, as uptake of novel pipeline products would be hindered by their premium price point.
Scope
- Overview of schizophrenia, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized schizophrenia market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
- Key topics covered include market characterization, unmet needs, R&D and clinical trials assessment, late stage clinical trial analysis and implications for the schizophrenia therapeutics market.
- Pipeline analysis: focus on nine late-stage pipeline schizophrenia drugs, discussing emerging trends as well as an overview of earlier phase drugs.
- Analysis of the current and future market competition in the global schizophrenia therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends shaping and driving the global schizophrenia therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global schizophrenia therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global schizophrenia therapeutics market from 2015-2025.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Companies Mentioned
Alexza Pharmaceuticals
Alkermes
Allergan
Almirall Prodesfarma
Astellas
AstraZeneca
Avanir Pharmaceuticals
Avineuro Pharmaceuticals
Braeburn Pharmaceuticals
Bristol-Myers Squibb
Dainippon Sumitomo/Sunovion
Eli Lilly
Epomedics
Ferrer
Gedeon Richter
HLS Therapeutics
Indivior
Intra-Cellular Therapies
Janssen
Laboratorios Farmaceuticos Rovi
Lundbeck
Meiji Seika
Merck & Co.
Minerva Neurosciences
Mitsubishi Tanabe Pharma
Neurocrine Biosciences
Nitto Denko Corporation
Novartis
Otsuka
Pfizer
Sandoz
Sanofi
SyneuRx
Takeda
Teva Pharmaceutical
Titan Pharmaceutical
Vanda Pharmaceuticals
Yoshitomi Yakuhin Corporation
'
1 Table of Contents
1 Table of Contents 10
1.1 List of Tables 16
1.2 List of Figures 23
2 Introduction 25
2.1 Catalyst 25
2.2 Related Reports 26
3 Disease Overview 27
3.1 Etiology and Pathophysiology 27
3.1.1 Etiology 27
3.1.2 Pathophysiology 29
3.2 Classification 31
3.3 Symptoms 35
3.4 Course 38
3.5 Prognosis 39
4 Epidemiology 41
4.1 Disease Background 41
4.2 Risk Factors and Comorbidities 42
4.3 Global Trends 45
4.3.1 US 46
4.3.2 5EU 46
4.3.3 Japan 47
4.4 Forecast Methodology 49
4.4.1 Sources Used 50
4.4.2 Forecast Assumptions and Methods 51
4.4.3 Sources Not Used 57
4.5 Epidemiological Forecast for Schizophrenia (2015-2025) 58
4.5.1 12-Month Diagnosed Prevalent Cases of Schizophrenia 58
4.5.2 Age-Specific 12-Month Diagnosed Prevalent Cases of Schizophrenia 60
4.5.3 Sex-Specific 12-Month Diagnosed Prevalent Cases of Schizophrenia 61
4.5.4 Age-Standardized 12-Month Diagnosed Prevalence of Schizophrenia 63
4.6 Discussion 64
4.6.1 Epidemiological Forecast Insight 64
4.6.2 Limitations of the Analysis 65
4.6.3 Strengths of the Analysis 66
5 Disease Management 67
5.1 Diagnosis Overview 67
5.1.1 Clinical Evaluation 67
5.2 Treatment Overview 69
5.2.1 Treatment Initiation 69
5.2.2 Maintenance Treatment 71
5.2.3 Treatment of Breakthrough Episodes 72
5.2.4 Long-Acting Injectables 73
5.2.5 Treatment-Resistance 75
5.2.6 Acute Agitation 79
5.2.7 Adjunctive Psychotherapy 80
5.3 Treatment Guidelines and Leading Prescribed Drugs 81
5.4 US 83
5.5 5EU 86
5.6 Japan 89
6 Competitive Assessment 93
6.1 Overview 93
6.2 Product Profiles - Atypical Antipsychotics 96
6.2.1 Abilify (aripiprazole) 96
6.2.2 Aristada (aripiprazole lauroxil) 109
6.2.3 Clozapine (widely genericized) 116
6.2.4 Fanapt (iloperidone) 123
6.2.5 Geodon (ziprasidone) 130
6.2.6 Invega (paliperidone) 135
6.2.7 Latuda (lurasidone) 149
6.2.8 Lonasen (blonanserin) 156
6.2.9 Rexulti (brexpiprazole) 161
6.2.10 Risperdal (risperidone) 167
6.2.11 Saphris (asenapine) 180
6.2.12 Seroquel (quetiapine) 187
6.2.13 Vraylar (cariprazine) 200
6.2.14 Zyprexa (olanzapine) 207
6.3 Product Profiles - Typical Antipsychotics 220
6.3.1 Typical Antipsychotics 220
6.3.2 Adasuve (Staccato loxapine) 224
6.4 Other Therapeutic Classes 230
7 Unmet Needs and Opportunities 231
7.1 Overview 231
7.2 Development of Cognitive-Enhancing Drugs 233
7.2.1 Unmet Need 233
7.2.2 Gap Analysis 234
7.2.3 Opportunity 234
7.3 Development of Drugs to Treat Negative Symptoms 234
7.3.1 Unmet Need 234
7.3.2 Gap Analysis 235
7.3.3 Opportunity 236
7.4 Improved Treatment Options for Treatment-Resistant Patients 236
7.4.1 Unmet Need 236
7.4.2 Gap Analysis 237
7.4.3 Opportunity 237
7.5 Development of Drugs with Enhanced Safety Profiles 238
7.5.1 Unmet Need 238
7.5.2 Gap Analysis 239
7.5.3 Opportunity 239
7.6 Development of Drugs to Increase Compliance 239
7.6.1 Unmet Need 239
7.6.2 Gap Analysis 241
7.6.3 Opportunity 241
8 Pipeline Assessment 242
8.1 Overview 242
8.1.1 Clinical Trials by Class of Therapy 242
8.2 Promising Drugs in Clinical Development 243
8.2.1 ALKS-3831 245
8.2.2 ITI-007 253
8.2.3 Lu AF35700 262
8.2.4 MIN-101 265
8.2.5 Risperidone implant 274
8.2.6 Risperidone ISM 281
8.2.7 RBP-7000 286
8.2.8 AVN-211 295
8.2.9 NaBen 303
8.3 Other Drugs in Development 311
9 Current and Future Players 314
9.1 Overview 314
9.2 Trends in Corporate Strategy 317
9.3 Company Profiles 319
9.3.1 Alkermes 319
9.3.2 Dainippon Sumitomo 321
9.3.3 Eli Lilly 324
9.3.4 Intra-Cellular Therapies 326
9.3.5 Janssen 328
9.3.6 Lundbeck 331
9.3.7 Minerva Neurosciences 334
9.3.8 Otsuka 336
10 Market Outlook 340
10.1 Global Markets 340
10.1.1 Forecast 340
10.1.2 Drivers and Barriers - Global Issues 344
10.2 US 344
10.2.1 Forecast 344
10.2.2 Key Events 348
10.2.3 Drivers and Barriers 349
10.3 5EU 349
10.3.1 Forecast 349
10.3.2 Key Events 352
10.3.3 Drivers and Barriers 353
10.4 Japan 353
10.4.1 Forecast 353
10.4.2 Key Events 356
10.4.3 Drivers and Barriers 357
11 Appendix 358
11.1 Bibliography 358
11.2 Abbreviations 400
11.3 Methodology 406
11.4 Forecasting Methodology 406
11.4.1 Diagnosed Schizophrenia Patients 406
11.4.2 Percent Drug-Treated Patients 407
11.4.3 Launch and Patent Expiry Dates 407
11.4.4 General Pricing Assumptions 408
11.4.5 Individual Drug Assumptions 409
11.4.6 Generic Erosion 424
11.4.7 Pricing of Pipeline Agents 424
11.5 Primary Research - KOLs Interviewed for this Report 426
11.6 Primary Research - Prescriber Survey 428
11.7 About the Authors 429
11.7.1 Analyst 429
11.7.2 Therapy Area Director 430
11.7.3 Epidemiologist 430
11.7.4 Managing Epidemiologist 431
11.7.5 Global Director of Therapy Analysis and Epidemiology 431
11.8 About GlobalData 432
11.9 Disclaimer 432
1.1 List of Tables
Table 1: DSM-V Schizophrenia Specifiers 32
Table 2: Classification of Schizophrenia According to DSM-IV and ICD-10 34
Table 3: Other Schizophrenia Spectrum Disorders, 2015 35
Table 4: Symptoms of Schizophrenia 37
Table 5: Risk Factors and Comorbidities for Schizophrenia 43
Table 6: 7MM, Sources of 12-Month Diagnosed Prevalence Data 50
Table 7: 7MM, 12-Month Diagnosed Prevalent Cases of Schizophrenia, Ages ≥13 Years, Both Sexes, N, Select Years, 2015-2025 59
Table 8: 7MM, Age-Specific 12-Month Diagnosed Prevalent Cases of Schizophrenia, Ages ≥13 Years, Both Sexes, N (Row %), 2015 60
Table 9: 7MM, Sex-Specific 12-Month Diagnosed Prevalent Cases of Schizophrenia, Ages ≥13 Years, N (Row %), 2015 62
Table 10: Treatment Guidelines for Schizophrenia 82
Table 11: Most Prescribed Drugs for Schizophrenia in the 7MM, 2015 83
Table 12: Country Profile - US 86
Table 13: Country Profile - 5EU 89
Table 14: Country Profile - Japan 92
Table 15: Leading Treatments for Schizophrenia, 2015 95
Table 16: Product Profile - Abilify 99
Table 17: Efficacy Results for Abilify in Schizophrenia Trials 101
Table 18: Efficacy Results for Abilify in Schizophrenia Trials 103
Table 19: AEs at ≥2% Incidence in Schizophrenia and Bipolar I Disorder Trials of Abilify 105
Table 20: AEs at ≥2% Incidence in a Schizophrenia Trial of Abilify Maintena 107
Table 21: Abilify SWOT Analysis, 2016 108
Table 22: Product Profile - Aristada 112
Table 23: Efficacy Results for Aristada in Schizophrenia Trial 113
Table 24: AEs at ≥2% Incidence in a Schizophrenia Trial of Aristada 114
Table 25: Aristada SWOT Analysis, 2016 115
Table 26: Product Profile - Clozapine 118
Table 27: Efficacy Results for Clozapine in Treatment-Resistant Schizophrenia Patients 119
Table 28: AEs at ≥5% Incidence in a Short-Term Trial of Clozapine 120
Table 29: AEs at ≥2% Incidence in All Clinical Trials of Clozapine (Excluding InterSePT) 121
Table 30: AEs at ≥10% Incidence During the InterSePT Trial of Clozapine 122
Table 31: Clozapine SWOT Analysis, 2016 123
Table 32: Product Profile - Fanapt 126
Table 33: AEs at ≥2% Incidence in Short-Term Trials of Fanapt 128
Table 34: Fanapt SWOT Analysis, 2016 129
Table 35: Product Profile - Geodon 131
Table 36: AEs at ≥2% Incidence in Schizophrenia Trials of Geodon 133
Table 37: Geodon SWOT Analysis, 2016 134
Table 38: Product Profile - Invega 138
Table 39: Efficacy of Invega Sustenna in Adult Schizophrenia Short-Term Trials 140
Table 40: AEs at ≥2% Incidence in Adult Schizophrenia Trials of Invega 142
Table 41: AEs at ≥2% Incidence in an Adolescent Schizophrenia Trial of Invega 143
Table 42: AEs at ≥2% Incidence in Schizophrenia Trials of Invega Sustenna 145
Table 43: AEs at ≥2% Incidence in a Long-Term Maintenance Trial of Invega Trinza in Schizophrenic Patients 147
Table 44: Invega SWOT Analysis, 2016 148
Table 45: Product Profile - Latuda 151
Table 46: Efficacy Results for Latuda in Schizophrenia Trials 153
Table 47: AEs at ≥2% Incidence in Schizophrenia Trials of Latuda 155
Table 48: Latuda SWOT Analysis, 2016 156
Table 49: Product Profile - Lonasen 158
Table 50: Efficacy Results for Lonasen in Haloperidol-Controlled Clinical Trial 158
Table 51: Efficacy Results for Lonasen in Risperidone-Controlled Clinical Trial 159
Table 52: AEs at ≥5% Incidence in a Short-Term Trial of Lonasen 160
Table 53: Lonasen SWOT Analysis, 2016 160
Table 54: Product Profile - Rexulti 163
Table 55: Efficacy Results for Rexulti in Short-Term Schizophrenia Trials 164
Table 56: AEs at ≥2% Incidence in Schizophrenia Trials of Rexulti 165
Table 57: Rexulti SWOT Analysis, 2016 166
Table 58: Product Profile - Risperdal 170
Table 59: Efficacy Results for Risperdal Consta in a 12-Week Schizophrenia Study 173
Table 60: AEs at ≥2% Incidence in Adult Schizophrenia Trials of Risperdal 175
Table 61: AEs at ≥5% Incidence in a Pediatric Schizophrenia Trial of Risperdal 177
Table 62: AEs at ≥5% Incidence in an Adult Schizophrenia Trial of Risperdal Consta 178
Table 63: Risperdal SWOT Analysis, 2016 179
Table 64: Product Profile - Saphris 182
Table 65: Efficacy Results for Saphris in Short-Term Schizophrenia Trials 183
Table 66: AEs at ≥2% Incidence in Schizophrenia Trials of Saphris 185
Table 67: Saphris SWOT Analysis, 2016 186
Table 68: Product Profile - Seroquel 190
Table 69: Efficacy Results for Seroquel in a Six-Week Schizophrenia Study 191
Table 70: Efficacy Results for Seroquel in Short-Term Schizophrenia Studies 193
Table 71: Efficacy Results for Seroquel XR in Schizophrenia Trials 194
Table 72: AEs at ≥2% Incidence in Adult Schizophrenia and Bipolar Mania Trials of Seroquel 196
Table 73: AEs at ≥2% Incidence in a Short-Term Trial of Seroquel in Schizophrenic Adolescents 197
Table 74: AEs at ≥2% Incidence in Six-Week Trials of Seroquel XR in Schizophrenic Adults 198
Table 75: Seroquel SWOT Analysis, 2016 199
Table 76: Product Profile - Vraylar 202
Table 77: Efficacy Results for Vraylar in a Six-Week Schizophrenia Study 203
Table 78: Efficacy Results for Vraylar in Short-Term Schizophrenia Studies 204
Table 79: AEs at ≥2% Incidence in Short-Term Schizophrenia Trials of Vraylar 205
Table 80: Vraylar SWOT Analysis, 2016 206
Table 81: Product Profile - Zyprexa 210
Table 82: AEs at ≥5% Incidence in Adult Schizophrenia Trials of Zyprexa 213
Table 83: AEs at ≥2% Incidence in Short-Term Trials of Zyprexa 214
Table 84: AEs at ≥1% Incidence in Adult Schizophrenia Trials of Zyprexa IntraMusular 215
Table 85: AEs at ≥5% Incidence in Adolescent Schizophrenia Trials of Zyprexa 216
Table 86: AEs Reported at ≥2% Incidence in a Schizophrenia Trial of Zyprexa Relprevv 217
Table 87: Zyprexa SWOT Analysis, 2016 219
Table 88: Typical antipsychotics SWOT Analysis, 2016 223
Table 89: Product Profile - Adasuve 226
Table 90: Efficacy Results for Adasuve in Agitation Trial of Schizophrenia Patients 227
Table 91: Decrease in FEV1 in Pulmonary Safety Trials of Adasuve 228
Table 92: Adasuve SWOT Analysis, 2016 229
Table 93: Summary of Minor Therapeutic Classes, 2015 230
Table 94: Unmet Need and Opportunity in Schizophrenia 233
Table 95: Product Profile - ALKS-3831 249
Table 96: ALKS-3831 SWOT Analysis, 2016 253
Table 97: Product Profile - ITI-007 256
Table 98: Efficacy Results for ITI-007 in a Phase II Schizophrenia Trial 257
Table 99: Key Safety Data From a Phase II in a Schizophrenia Trial of ITI-007 259
Table 100: ITI-007 SWOT Analysis, 2016 261
Table 101: Product Profile - Lu AF35700 263
Table 102: Lu AF35700 SWOT Analysis, 2016 265
Table 103: Product Profile - MIN-101 267
Table 104: Efficacy Results for MIN-101 in a 12-Week Phase IIb Schizophrenia Study 269
Table 105: Safety Evaluation of MIN-101 Phase IIa Clinical Trial in Schizophrenia 270
Table 106: AEs at ≥5% Incidence in a Phase IIb Schizophrenia Trial of MIN-101 271
Table 107: Safety Evaluation of MIN-101 Phase IIb Clinical Trial in Schizophrenia 271
Table 108: MIN-101 SWOT Analysis, 2016 274
Table 109: Product Profile - Risperidone Implant 277
Table 110: Risperidone Implant SWOT Analysis, 2016 280
Table 111: Product Profile - Risperidone ISM 282
Table 112: Risperidone ISM SWOT Analysis, 2016 285
Table 113: Product Profile - RBP-7000 288
Table 114: Efficacy Results for RBP-7000 in a Phase III Schizophrenia Trial 289
Table 115: AEs reported in a Phase III Schizophrenia Trial of RBP-7000A 291
Table 116: RBP-7000 SWOT Analysis, 2016 294
Table 117: Product Profile - AVN-211 296
Table 118: Attention tests and measures evaluated in a Phase IIa Schizophrenia Trial of AVN-211 297
Table 119: Psychometric Results in a Phase IIa Schizophrenia Trial of AVN-211 299
Table 120: Results of the Attention Measures that Showed Significant Changes in a Phase IIa Schizophrenia Trial of AVN-211 300
Table 121: AVN-211 SWOT Analysis, 2016 302
Table 122: Product Profile - NaBen 304
Table 123: PANSS Clinical Measures During the Phase II Trial of Sodium Benzoate Adjunctive Therapy in Schizophrenia 306
Table 124: Other Clinical Measures During the Phase II Trial of Sodium Benzoate Adjunctive Therapy in Schizophrenia 307
Table 125: Cognitive Measures During the Phase II Trial of Sodium Benzoate Adjunctive Therapy in Schizophrenia 308
Table 126: NaBen SWOT Analysis, 2016 310
Table 127: Drugs in Development for Schizophrenia, 2015 312
Table 128: Key Companies in the Schizophrenia Market in the 7MM, 2015 315
Table 129: Alkermes’ Schizophrenia Portfolio Assessment, 2015 320
Table 130: Alkermes SWOT Analysis in Schizophrenia, 2015-2025 321
Table 131: Dainippon Sumitomo’s Schizophrenia Portfolio Assessment, 2015 323
Table 132: Dainippon Sumitomo SWOT Analysis in Schizophrenia, 2015-2025 324
Table 133: Eli Lilly’s Schizophrenia Portfolio Assessment, 2015 325
Table 134: Eli Lilly SWOT Analysis in Schizophrenia, 2015-2025 326
Table 135: Intra-Cellular Therapies’ Schizophrenia Portfolio Assessment, 2015 327
Table 136: Intra-Cellular Therapies SWOT Analysis in Schizophrenia, 2015-2025 328
Table 137: Janssen’s Schizophrenia Portfolio Assessment, 2015 330
Table 138: Janssen SWOT Analysis in Schizophrenia, 2015-2025 331
Table 139: Lundbeck’s Schizophrenia Portfolio Assessment, 2015 333
Table 140: Lundbeck SWOT Analysis in Schizophrenia, 2015-2025 334
Table 141: Minerva Neurosciences’ Schizophrenia Portfolio Assessment, 2015 335
Table 142: Minerva Neurosciences SWOT Analysis in Schizophrenia, 2015-2025 336
Table 143: Otsuka’s Schizophrenia Portfolio Assessment, 2015 338
Table 144: Otsuka SWOT Analysis in Schizophrenia, 2015-2025 339
Table 145: Schizophrenia Market - Drivers and Barriers, 2015-2025 344
Table 146: Key Events Impacting Sales for Schizophrenia in the US, 2015-2025 348
Table 147: Schizophrenia Market in the US - Drivers and Barriers, 2015-2025 349
Table 148: Key Events Impacting Sales for Schizophrenia in the 5EU, 2015-2025 352
Table 149: Schizophrenia Market in the 5EU - Drivers and Barriers, 2015-2025 353
Table 150: Key Events Impacting Sales for Schizophrenia in Japan, 2015-2025 356
Table 151: Schizophrenia Market in Japan - Drivers and Barriers, 2015-2025 357
Table 152: Key Launch Dates 407
Table 153: Key Patent/Exclusivity Expiries 408
Table 154: High-Prescribing Psychiatrists (Non-KOLs) Surveyed, By Country 428
1.2 List of Figures
Figure 1: Longitudinal Course of Schizophrenia 39
Figure 2: 7MM, 12-Month Diagnosed Prevalent Cases of Schizophrenia, Ages ≥13 Years, Both Sexes, N, Select Years, 2015-2025 59
Figure 3: 7MM, Age-Specific 12-Month Diagnosed Prevalent Cases of Schizophrenia, Ages ≥13 Years, Both Sexes, N, 2015 61
Figure 4: 7MM, Sex-Specific 12-Month Diagnosed Prevalent Cases of Schizophrenia, Ages ≥13 Years, N, 2015 63
Figure 5: 7MM, Age-Standardized 12-Month Diagnosed Prevalence of Schizophrenia (Cases per 100,000 Population), Ages ≥13 Years, Both Sexes, 2015 64
Figure 6: Schizophrenia Therapeutics - Class of Therapy, 2016 243
Figure 7: Schizophrenia - Promising Late-Stage Phase IIb-III Pipeline Drugs, 2016 244
Figure 8: Competitive Assessment of Promising Late-Stage Pipeline Agents in Schizophrenia, 2015-2025 245
Figure 9: Clinical and Commercial Positioning of ALKS-3831 252
Figure 10: Clinical and Commercial Positioning of ITI-007 260
Figure 11: Clinical and Commercial Positioning of Lu AF35700 264
Figure 12: Clinical and Commercial Positioning of MIN-101 273
Figure 13: Clinical and Commercial Positioning of the Risperidone Implant 279
Figure 14: Clinical and Commercial Positioning of Risperidone ISM 284
Figure 15: Clinical and Commercial Positioning of RBP-7000 293
Figure 16: Clinical and Commercial Positioning of AVN-211 302
Figure 17: Clinical and Commercial Positioning of NaBen 310
Figure 18: Global Sales of Products for Schizophrenia by Company, 2015-2025 316
Figure 19: Company Portfolio Gap Analysis in Schizophrenia, 2015-2025 317
Figure 20: Global Sales for Schizophrenia by Region, 2015-2025 342
Figure 21: Global Sales for Schizophrenia by Drug Class, 2015-2025 343
Figure 22: Sales for Schizophrenia in the US by Drug Class, 2015-2025 347
Figure 23: Sales for Schizophrenia in the 5EU by Drug Class, 2015-2025 351
Figure 24: Sales for Schizophrenia in Japan by Drug Class, 2015-2025 355
